TRIM14 Antibody

What is TRIM14 and why is it significant for immunological research?

TRIM14 belongs to the tripartite motif family of proteins that contains a B-box, a coiled-coil, and a C-terminal PRYSPRY domain but notably lacks the N-terminal RING domain that exists in most TRIM family proteins. It plays key roles in cellular proliferation, differentiation, development, and immune signaling.

TRIM14 is particularly significant because:

• It facilitates the assembly of the MAVS (mitochondrial antiviral-signaling protein) complex during innate immune responses against viruses

• It serves as a mitochondrial adaptor that recruits NEMO (NF-κB essential modulator) to the MAVS signalosome

• It activates both the IFN regulatory factor 3 and NF-κB pathways, leading to type I interferon production

• It participates in epigenetic regulation by stabilizing the histone demethylase KDM4D

What are the typical applications for TRIM14 antibodies in basic research?

TRIM14 antibodies can be used in multiple experimental applications including:

For optimal results, researchers should validate the antibody in their specific experimental system, as reactivity may vary between human and mouse samples .

How can I confirm the specificity of TRIM14 antibody for my experiments?

To confirm TRIM14 antibody specificity:

• Include proper controls:

  • Positive control: Cell lines known to express TRIM14 (e.g., L02, HL-60, HepG2, Jurkat cells)

  • Negative control: TRIM14 knockout cells or TRIM14 siRNA-treated cells

• Verify molecular weight:

  • TRIM14 has a calculated molecular weight of 50 kDa (442 amino acids)

  • Confirm that your antibody detects a band at approximately 50 kDa in Western blot

• Cross-validate with multiple detection methods:

  • Compare results from different applications (WB, IF, IHC)

  • Use alternative antibodies targeting different epitopes of TRIM14

  • Consider mass spectrometry validation for immunoprecipitation experiments

• If possible, include TRIM14 knockout samples as the definitive negative control

How can TRIM14 antibodies be used to study mitochondrial localization and MAVS interaction?

TRIM14 localizes to the outer membrane of mitochondria and interacts with MAVS to facilitate antiviral signaling. To study this interaction:

• Co-immunoprecipitation with TRIM14 antibodies:

  • Use TRIM14 antibodies to pull down TRIM14-MAVS complexes

  • Analyze viral infection-induced enhancement of this interaction

  • The association between endogenous TRIM14 and MAVS is enhanced upon viral infection

• Immunofluorescence co-localization studies:

  • Perform dual staining with TRIM14 antibody and mitochondrial markers or MAVS

  • Analyze co-localization before and after viral infection

  • Observe recruitment patterns during innate immune activation

• Size-exclusion chromatography:

  • TRIM14 co-elutes with MAVS in a complex of approximately 600 kDa

  • Upon viral infection, both MAVS and TRIM14 migrate to higher molecular weight fractions

  • Use TRIM14 antibodies for Western blot analysis of these fractions

• Domain mapping:

  • The C-terminal domain of MAVS (residues 360–540) and the PRYSPRY domain of TRIM14 are critical for their interaction

  • Use truncated constructs with TRIM14 antibodies to validate interaction domains

How can researchers investigate TRIM14's role in TBK1-STAT3 signaling using TRIM14 antibodies?

TRIM14 acts as a scaffold between TBK1 and STAT3 to promote STAT3 phosphorylation and regulate interferon signaling:

• Co-immunoprecipitation studies:

  • Use TRIM14 antibodies to pull down TBK1-TRIM14-STAT3 complexes

  • Analyze phosphorylation status of STAT3 at Ser727

  • Compare wild-type to TRIM14 knockout or knockdown cells

• Proximity ligation assay:

  • Utilize TRIM14 antibodies with TBK1 or STAT3 antibodies

  • Visualize protein-protein interactions in situ

  • Quantify interaction frequency under different stimulation conditions

• Immunoblotting for signaling dynamics:

  • Monitor TRIM14-dependent phosphorylation of STAT3

  • Analyze IFNAR signaling components

  • Compare ISG expression in TRIM14-sufficient vs. TRIM14-deficient cells

• Chromatin immunoprecipitation (ChIP):

  • Use TRIM14 and STAT3 antibodies to investigate promoter occupancy

  • Analyze binding to ISG promoters

  • Correlate with gene expression data

What approaches can be used to study TRIM14's role in KDM4D stabilization and epigenetic regulation?

TRIM14 stabilizes KDM4D by preventing its autophagic degradation, affecting histone H3K9 trimethylation and inflammatory gene expression:

• Sequential immunoprecipitation:

  • First IP: Pull down TRIM14 using TRIM14 antibodies

  • Second IP: Detect associated deubiquitinases (USP14, BRCC3) and KDM4D

  • Analyze ubiquitination status of KDM4D in these complexes

• ChIP-seq analysis:

  • Use TRIM14 antibodies alongside H3K9me3 and KDM4D antibodies

  • Compare chromatin landscapes at inflammatory gene loci (e.g., Il12, Il23)

  • Correlate with gene expression changes

• Autophagic flux assays:

  • Use TRIM14 antibodies to monitor TRIM14-KDM4D-OPTN interactions

  • Analyze how TRIM14 affects KDM4D degradation under autophagy-inducing conditions

  • Quantify LC3 puncta formation and colocalization with KDM4D

• Ubiquitination analysis:

  • Immunoprecipitate KDM4D and probe for K63-linked ubiquitin chains

  • Compare between wild-type and TRIM14-deficient conditions

  • Analyze recruitment of deubiquitinases USP14 and BRCC3

What are the optimal conditions for using TRIM14 antibodies in immunofluorescence studies?

For optimal immunofluorescence results with TRIM14 antibodies:

• Sample preparation:

  • Fixation: 4% paraformaldehyde for 15-20 minutes at room temperature

  • Permeabilization: 0.1-0.5% Triton X-100 for 5-10 minutes

  • Blocking: 5% BSA or normal serum for 1 hour

• Antibody application:

  • Primary antibody dilution: 1:200-1:800 for TRIM14 antibody

  • Incubation: Overnight at 4°C or 1-2 hours at room temperature

  • Secondary antibody: Fluorophore-conjugated anti-rabbit IgG at 1:500-1:1000

  • Include DAPI or other nuclear counterstain

• Mitochondrial co-localization:

  • Co-stain with mitochondrial markers (MitoTracker, TOM20, or MAVS)

  • Use confocal microscopy for high-resolution imaging

  • Quantify co-localization using Pearson's or Mander's coefficient

• Signal enhancement for detection of endogenous TRIM14:

  • Consider tyramide signal amplification if endogenous levels are low

  • Optimize antigen retrieval if using paraformaldehyde-fixed tissue sections

How should researchers design experiments to study TRIM14's role in viral infection using TRIM14 antibodies?

To study TRIM14's role during viral infection:

• Experimental design:

  • Cell types: Use cell lines with robust TRIM14 expression (e.g., HepG2, Jurkat)

  • Viral stimulation: SeV (Sendai virus), poly(I:C), or VSV (vesicular stomatitis virus)

  • Timepoints: 0, 3, 6, 12, 24 hours post-infection

  • Controls: TRIM14 knockout/knockdown cells, mock-infected cells

• Protein-level analysis:

  • Western blot: Monitor TRIM14 upregulation using antibodies (1:500-1:2000 dilution)

  • Subcellular fractionation: Analyze TRIM14 recruitment to mitochondria

  • Co-immunoprecipitation: Study TRIM14-MAVS interaction dynamics

  • Phosphorylation analysis: Monitor IRF3 phosphorylation and IκBα phosphorylation

• Functional assays:

  • Reporter assays: IFN-β, ISRE, and NF-κB promoter activities

  • Viral replication: Plaque assays to quantify effects of TRIM14 manipulation

  • Gene expression: qPCR analysis of IFNB1, ISG56, ISG15, and TNFA expression

• Microscopy:

  • Track TRIM14 localization during infection using immunofluorescence

  • Analyze formation of signaling complexes using proximity ligation assay

  • Quantify viral replication in TRIM14-sufficient vs. TRIM14-deficient cells

What controls should be included when using TRIM14 antibodies in immunoprecipitation experiments?

For robust immunoprecipitation experiments with TRIM14 antibodies:

• Essential controls:

  • Input control: 5-10% of the lysate used for IP

  • IgG control: Non-specific IgG from the same species as the TRIM14 antibody

  • Knockout/knockdown control: Lysate from TRIM14-depleted cells

  • Blocking peptide control: Pre-incubation of antibody with immunizing peptide

• Validation controls:

  • Reciprocal IP: Immunoprecipitate with antibodies against TRIM14 interacting partners (MAVS, TBK1, STAT3)

  • Sequential IP: Two rounds of immunoprecipitation to confirm complex formation

  • Crosslinking controls: Compare results with and without protein crosslinking

• Application-specific controls:

  • For ubiquitination studies: Include deubiquitinase inhibitors (e.g., N-ethylmaleimide)

  • For phosphorylation studies: Include phosphatase inhibitors

  • For studying transient interactions: Use stimulus conditions (e.g., viral infection) that enhance the interaction

• Technical considerations:

  • Detergent selection: Use mild detergents (e.g., 0.5% NP-40) to preserve protein-protein interactions

  • Salt concentration: Optimize to maintain specific interactions while reducing background

  • Pre-clearing: Pre-clear lysates with protein A/G beads to reduce non-specific binding

How can researchers address non-specific binding issues with TRIM14 antibodies?

If experiencing non-specific binding with TRIM14 antibodies:

• Antibody optimization:

  • Titrate antibody concentration (try more dilute solutions)

  • Optimize incubation time and temperature

  • Use freshly prepared antibody dilutions

• Sample preparation improvements:

  • Increase blocking time and concentration (5-10% BSA or serum)

  • Add 0.1-0.5% Tween-20 to wash buffers

  • Pre-absorb antibody with cell lysate from TRIM14 knockout cells

• Protocol modifications:

  • For Western blot: Use PVDF membrane instead of nitrocellulose

  • For IHC/IF: Optimize antigen retrieval (TE buffer pH 9.0 or citrate buffer pH 6.0)

  • For IP: Increase number and duration of washes

• Validation approaches:

  • Compare multiple TRIM14 antibodies targeting different epitopes

  • Verify with siRNA/shRNA knockdown or CRISPR knockout controls

  • Perform peptide competition assay with the immunizing peptide

How should researchers interpret changes in TRIM14 localization during immune responses?

When analyzing TRIM14 localization changes:

• Expected patterns:

  • Basal state: Diffuse cytoplasmic and mitochondrial localization

  • After viral infection: Increased mitochondrial localization and co-localization with MAVS

  • Complex formation: Migration into higher molecular weight fractions in size exclusion chromatography

• Quantitative analysis:

  • Measure co-localization coefficients with mitochondrial markers

  • Quantify nuclear vs. cytoplasmic distribution

  • Track temporal changes following stimulation

  • Compare with MAVS, TBK1, or other signaling partners

• Functional correlation:

  • Correlate localization changes with activation of downstream signaling (IRF3, NF-κB)

  • Link subcellular distribution to gene expression changes (IFN-β, ISGs)

  • Compare wild-type TRIM14 with domain mutants (e.g., ΔPRYSPRY)

• Technical considerations:

  • Use high-resolution imaging (confocal or super-resolution microscopy)

  • Include appropriate subcellular markers

  • Consider live-cell imaging with fluorescently tagged TRIM14 to complement antibody-based fixed-cell imaging

How can researchers reconcile contradictory data regarding TRIM14's role in different disease models?

When facing contradictory results about TRIM14 function:

• Context-dependent functions:

  • TRIM14 serves both antiviral and antibacterial roles

  • In viral infections: TRIM14 promotes type I IFN responses by facilitating MAVS signaling

  • In M. tuberculosis infection: TRIM14 deficiency leads to enhanced bacterial control through hyperinduction of iNOS

  • In autoimmune models: TRIM14 deficiency protects against EAE by reducing inflammatory cytokine production

• Methodological reconciliation:

  • Compare experimental systems (cell types, stimuli, timepoints)

  • Evaluate knockout/knockdown efficiency and specificity

  • Assess potential compensation by other TRIM family members

  • Consider post-translational modifications and protein interactions specific to each context

• Mechanistic integration:

  • TRIM14 regulates both STAT3 activation and TBK1 signaling

  • It affects both epigenetic regulation through KDM4D and direct immune signaling through MAVS

  • Different disease models may highlight distinct aspects of these multifaceted functions

• Experimental approaches to resolve contradictions:

  • Domain mapping studies to identify context-specific interactions

  • Tissue-specific knockout models to address cell type-specific functions

  • Temporal regulation studies to distinguish early vs. late effects

  • Systems biology approaches to model the complex signaling networks involving TRIM14

What are emerging applications of TRIM14 antibodies in studying autoimmune diseases?

TRIM14 has significant implications for autoimmune research:

• Experimental autoimmune encephalomyelitis (EAE) studies:

  • TRIM14 deficiency protects mice from EAE with reduced clinical symptom severity

  • Decreased infiltration of immune cells into the brain

  • Reduced IL17A+CD4+ and IL21+CD4+ cells in the CNS

  • Lowered mRNA levels of Il12a, Il12b, and Il23a in spinal cord and brain tissue

• Research applications:

  • Use TRIM14 antibodies to track protein expression in immune cells during disease progression

  • Monitor KDM4D-TRIM14 interaction in different disease states

  • Analyze H3K9 trimethylation patterns at inflammatory gene loci

  • Study TRIM14 expression in patient samples from autoimmune conditions

• Mechanistic investigations:

  • Examine how TRIM14 regulates the balance between pro-inflammatory and anti-inflammatory responses

  • Study TRIM14's role in different immune cell subsets (dendritic cells, T cells, macrophages)

  • Investigate potential therapeutic approaches targeting TRIM14 pathways

• Technical considerations:

  • Use immunohistochemistry with TRIM14 antibodies on tissue sections from autoimmune disease models

  • Employ flow cytometry with intracellular TRIM14 staining to analyze immune cell populations

  • Apply single-cell approaches to assess TRIM14 expression heterogeneity

How can researchers use TRIM14 antibodies to investigate its role in autophagy regulation?

TRIM14 plays a crucial role in preventing autophagic degradation of proteins like KDM4D:

• Experimental approaches:

  • Co-immunoprecipitation with TRIM14 antibodies to detect interactions with autophagy proteins

  • Immunofluorescence to study co-localization with autophagosome markers (LC3)

  • Western blot analysis of autophagic flux in the presence or absence of TRIM14

  • Proximity ligation assays to detect TRIM14-optineurin-KDM4D interactions

• Mechanistic studies:

  • Analyze how TRIM14 recruits deubiquitinases (USP14, BRCC3) to substrates

  • Investigate how TRIM14 prevents K63-linked ubiquitination-dependent targeting to autophagosomes

  • Study competition between TRIM14 and optineurin for substrate binding

  • Examine effects of autophagy inducers/inhibitors on TRIM14-substrate interactions

• Disease relevance:

  • Investigate connections between TRIM14-mediated autophagy regulation and autoimmune disorders

  • Study links between TRIM14, autophagy, and antimicrobial responses

  • Explore potential therapeutic applications targeting this pathway

• Technical considerations:

  • Use bafilomycin A1 or chloroquine to block autophagosome-lysosome fusion

  • Compare autophagy substrate levels between wild-type and TRIM14-deficient cells

  • Monitor autophagic flux using tandem fluorescent-tagged LC3 reporters